CDH17-targeted CAR-NK cells combined with CV1 demonstrate enhanced anti-tumor activity in GI cancers by promoting macrophage activation and increasing M1 macrophage numbers, offering a promising therapeutic strategy. The gene discussed is CDH17; the disease is neoplasm.